Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An 18F-FDG PET Study
暂无分享,去创建一个
A. Ho | W. Weber | R. Tuttle | R. Grewal | J. Nagarajah
[1] H. Ryu,et al. The value of preoperative PET–CT in papillary thyroid cancer , 2013, The Journal of international medical research.
[2] R. Celestino,et al. Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas , 2011, Current genomics.
[3] K. Schmid,et al. The BRAF V600E mutation in papillary thyroid carcinoma is associated with glucose transporter 1 overexpression. , 2011, Thyroid : official journal of the American Thyroid Association.
[4] M. Ladanyi,et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. , 2009, Cancer research.
[5] B. Cha,et al. Non-FDG-avid primary papillary thyroid carcinoma may not differ from FDG-avid papillary thyroid carcinoma. , 2013, Thyroid : official journal of the American Thyroid Association.
[6] Mithat Gonen,et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. , 2006, The Journal of clinical endocrinology and metabolism.
[7] M. Shah,et al. Role of BRAF in Thyroid Oncogenesis , 2011, Clinical Cancer Research.
[8] A. Bockisch,et al. Glucose Transporter 1 Expression, Tumor Proliferation, and Iodine/Glucose Uptake in Thyroid Cancer With Emphasis on Poorly Differentiated Thyroid Carcinoma , 2012, Clinical nuclear medicine.
[9] Bo Hyun Kim,et al. Diagnostic value of metabolic tumor volume assessed by 18F-FDG PET/CT added to SUVmax for characterization of thyroid 18F-FDG incidentaloma , 2013, Nuclear medicine communications.
[10] Yuri E Nikiforov,et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.
[11] Jason Li,et al. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. , 2014, Cancer discovery.
[12] K. Kinzler,et al. Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells , 2009, Science.
[13] P. Ward,et al. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.
[14] Y. Erdi,et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] P. Ladenson,et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. , 2013, JAMA.
[16] A. Piccardo,et al. Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas. , 2012, The Journal of clinical endocrinology and metabolism.
[17] Chris Sander,et al. 18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. , 2011, Cancer research.
[18] Z. Keidar,et al. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.